NCT06195124View on ClinicalTrials.gov

A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced Parkinson's Disease
Interventions
DRUG

RGL-193（low-dose）

Each side of the putamen received 150 μL of RGL-193, with a unilateral dose of 1.5×10\^11 VG and a bilateral dose of 3.0×10\^11 VG.

DRUG

RGL-193（high-dose）

Each side of the putamen received 200 μL of RGL-193, with a unilateral dose of 5.0×10\^11 VG and a bilateral dose of 1.0×10\^12 VG.

Trial Locations (1)

215004

RECRUITING

Department of Neurology, Second Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

Shanghai Regenelead Therapies Co., Ltd.

INDUSTRY

lead

Second Affiliated Hospital of Soochow University

OTHER